Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-riskneuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial

Ruth Ladenstein; Ulrike Pötschger; Andrew DJ Pearson; Penelope Brock; Roberto Luksch; Victoria Castel; Isaac Yaniv; Vassilios Papadakis; Geneviéve Laureys; Joesf Malis; Walentyna Balwierz; Ellen Ruud; Per Kogner; Henrik Schroeder; Ana Forjaz de Lacerda; Maja Beck-Popovic; Pavel Bician; Miklós Garami; Toby Trahair; Adela Canete; Peter F Ambros; Keith Holmes; Mark Gaze; Günter Schreier; Alberto Garaventa; Gilles Vassal; Jean Michon; Dominique Valteau-Couanet

Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-riskneuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial

Ruth Ladenstein
, Ulrike Pötschger
, Andrew DJ Pearson
, Penelope Brock
, Roberto Luksch
, Victoria Castel
, Isaac Yaniv
, Vassilios Papadakis
, Geneviéve Laureys
, Joesf Malis
, Walentyna Balwierz
, Ellen Ruud
, Per Kogner
, Henrik Schroeder
, Ana Forjaz de Lacerda
, Maja Beck-Popovic
, Pavel Bician
, Miklós Garami
, Toby Trahair
, Adela Canete

Peter F Ambros, Keith Holmes, Mark Gaze, Günter Schreier, Alberto Garaventa, Gilles Vassal, Jean Michon, Dominique Valteau-Couanet

Digital Health Information Systems

Department Oncology, St. Anna Children’s Hospital
Hospital Universitario y Politécnico de La Fe
Department of Paediatrics, University Hospital of Aarhus
Sydney Children's Hospital
St. Anna Children’s Cancer Research Institute (CCRI)

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	423-424
Number of pages	2
Journal	Lancet Oncology
Volume	18
Publication status	Published - 2017

Research Field

Not defined

Cite this

Ladenstein, R., Pötschger, U., Pearson, A. DJ., Brock, P., Luksch, R., Castel, V., Yaniv, I., Papadakis, V., Laureys, G., Malis, J., Balwierz, W., Ruud, E., Kogner, P., Schroeder, H., Forjaz de Lacerda, A., Beck-Popovic, M., Bician, P., Garami, M., Trahair, T., ... Valteau-Couanet, D. (2017). Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-riskneuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. Lancet Oncology, 18, 423-424.

@article{3a985be5a39f419e8fa282cd59acd7c9,

title = "Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-riskneuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial",

author = "Ruth Ladenstein and Ulrike P{\"o}tschger and Pearson, \{Andrew DJ\} and Penelope Brock and Roberto Luksch and Victoria Castel and Isaac Yaniv and Vassilios Papadakis and Genevi{\'e}ve Laureys and Joesf Malis and Walentyna Balwierz and Ellen Ruud and Per Kogner and Henrik Schroeder and \{Forjaz de Lacerda\}, Ana and Maja Beck-Popovic and Pavel Bician and Mikl{\'o}s Garami and Toby Trahair and Adela Canete and Ambros, \{Peter F\} and Keith Holmes and Mark Gaze and G{\"u}nter Schreier and Alberto Garaventa and Gilles Vassal and Jean Michon and Dominique Valteau-Couanet",

year = "2017",

language = "English",

volume = "18",

pages = "423--424",

journal = "Lancet Oncology",

issn = "1470-2045",

publisher = "Elsevier Ltd.",

}

Ladenstein, R, Pötschger, U, Pearson, ADJ, Brock, P, Luksch, R, Castel, V, Yaniv, I, Papadakis, V, Laureys, G, Malis, J, Balwierz, W, Ruud, E, Kogner, P, Schroeder, H, Forjaz de Lacerda, A, Beck-Popovic, M, Bician, P, Garami, M, Trahair, T, Canete, A, Ambros, PF, Holmes, K, Gaze, M, Schreier, G, Garaventa, A, Vassal, G, Michon, J & Valteau-Couanet, D 2017, 'Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-riskneuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial', Lancet Oncology, vol. 18, pp. 423-424.

Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-riskneuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. / Ladenstein, Ruth; Pötschger, Ulrike; Pearson, Andrew DJ et al.
In: Lancet Oncology, Vol. 18, 2017, p. 423-424.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-riskneuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial

AU - Ladenstein, Ruth

AU - Pötschger, Ulrike

AU - Pearson, Andrew DJ

AU - Brock, Penelope

AU - Luksch, Roberto

AU - Castel, Victoria

AU - Yaniv, Isaac

AU - Papadakis, Vassilios

AU - Laureys, Geneviéve

AU - Malis, Joesf

AU - Balwierz, Walentyna

AU - Ruud, Ellen

AU - Kogner, Per

AU - Schroeder, Henrik

AU - Forjaz de Lacerda, Ana

AU - Beck-Popovic, Maja

AU - Bician, Pavel

AU - Garami, Miklós

AU - Trahair, Toby

AU - Canete, Adela

AU - Ambros, Peter F

AU - Holmes, Keith

AU - Gaze, Mark

AU - Schreier, Günter

AU - Garaventa, Alberto

AU - Vassal, Gilles

AU - Michon, Jean

AU - Valteau-Couanet, Dominique

PY - 2017

Y1 - 2017

M3 - Article

SN - 1470-2045

VL - 18

SP - 423

EP - 424

JO - Lancet Oncology

JF - Lancet Oncology

ER -